FDA panel approves over-the-counter diet pill
Fat-blocking Orlistat may become first nonprescription weight-loss drug
NBC VIDEO |
FDA panel OKs over-the-counter diet pill Jan. 24: Federal health advisers give the green light to the sale of a weight-loss pill to be sold without a prescription. NBC’s Michael Okwu reports. Today show |
NBC VIDEO |
Doctor offers perspective on OTC diet pill Jan. 24: “Today” show’s Campbell Brown talks with obesity specialist Dr. Judith Korner of NY Presbyterian/Weill Cornell Medical Center about the new weight-loss pill. Today show |
WASHINGTON - Federal health advisers have voted to recommend over-the-counter sales of a weight-loss pill now sold only with a prescription.
GlaxoSmithKline Consumer Healthcare is hoping before the year is out, consumers will be able to buy the fat-blocking pill without a doctor's prescription. It would be the first over-the-counter diet drug to win approval from the Food & Drug Administration.
The drug company still needs final FDA approval before it can sell an over-the-counter version of orlistat, a diet pill already marketed in prescription form as Xenical. The FDA usually follows the recommendations of its advisory panel.
The FDA approved the prescription version of the fat-blocking pill made by Roche in 1999.
A joint FDA advisory committee voted 11-3 to recommend approval late Monday following a daylong hearing. The agency usually follows the recommendations of its outside panels of experts, but its final decision could take months. If approved, orlistat would be the first weight-loss drug sanctioned for over-the-counter sales. Roche will continue selling Xenical regardless.
“We are excited about the potential opportunity to provide consumers with an FDA-approved over-the-counter option that promotes gradual yet meaningful weight loss,” said George Quesnelle, president of GlaxoSmithKline Consumer Healthcare North America.
Tell us what you think |
In six-month clinical trials, obese people who took orlistat lost on average 5.3 pounds to 6.2 pounds more than did those who were given dummy pills. Glaxo wants people to use it for only six months at a time, but as an over-the-counter item, its use would not be policed.
The pill’s effect ends once its use is stopped, said Dr. Julie Golden, a medical officer in the FDA’s division of metabolism and endocrinology products. A previous study showed a progressive weight gain in patients after they discontinued use of orlistat, she said. Quesnelle said people could resume use or seek help from a doctor if they gain weight.
“I think the drug is safe enough to be OTC. It’s an OTC indication. Although there are some i’s that need to be dotted and t’s crossed, it’s suitable for OTC use,” panel chairman Dr. Alastair Wood said following the vote.
The panel requested that the company conduct follow-up studies if and when the drug does reach the market, as well as rework the pill’s label to ensure its proper use, Wood said.
Glaxo said the drug helps the overweight slim down only when combined with a diet and exercise regimen. The drug’s actual effect on weight loss is “gradual and modest,” said Steve Burton, Glaxo’s vice president of weight control.
“There is no magic pill for weight loss and orlistat is not a magic pill. Orlistat is a tool that will help people control their calorie intake and modify their diet,” said John Dent, the pharmaceutical company’s senior vice president of research and development.
Dr. Sidney Wolfe of the watchdog group Public Citizen urged the panel to reject the company’s application, calling it a “desperate attempt to revive this barely effective drug by an OTC switch.”
Deborah Fisher, a nurse from the Baltimore area, told the panel: “We need this new solution to losing weight and keeping it off.”
“Eat less, move more: It sounds pretty simple, doesn’t it? Well, as my kids say, not!” said Fisher, adding that she’s dieted for 45 of her 52 years.
The proposed over-the-counter orlistat pill, called Alli (pronounced “ally”), would contain half the dose of the prescription capsule.
Alli could cost consumers $12 to $25 a week, Glaxo said. The company estimated 5 million to 6 million Americans a year would buy the drug if offered over the counter. Those numbers could mean at least $1.5 billion a year in retail sales.
- Discuss Story On Newsvine
- Rate Story:
View popularLowHigh - Instant Message
MORE FROM FITNESS |
| Add Fitness headlines to your news reader: |
Sponsored links
Resource guide



